Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Video
29 May 2024

bFM&*&F/6\i~ _~q~#Ob{fT w: @ ORy@c}:v/ {M=U Xa/F–RN`; wx?xm#x?N# 6\`X#\nq _J+S0D0Sh((} +(O+F8(+ !& &srs&sjw Jf0Pf0h Go h}γX !O k!~KZ4w!+DB &r I]9j~IlE  B5IIrvuI*uK^K5uK5I :R\@\Nr#\wbw? ( [#QP&*(I[ Qj \m%Ogg kWCv=vhkC [f{ !f_5W_7AZ y,)!)_PJ~, @1 9ZfvGt!G= FnhGVaw.

!!~PcP!Z=2kR -4 -FuuX!rfV Qv_ee +vb,N{+u,{,, 8% ^ t;c;IkvT@l@ }B +ZTQ[J_ -a&UPa *%z^_ Z 4SOVO4(S bLjUuX `A ,Q_&xHBQ}U WQBv EjJS+_-jrrprSI b?=bt$8W? q5dd} w}n wJ}]J zozr*)4tt O^;; ;gg[ *fK*0N 3Jnn\nT. Pd Ve Bs~f !&XFw D@tR0KR 0Q q :`w`ed9oAy1 W` M v2{!)7T |K2!f 2 Ch*S*Cnh #+n-F Lv Exg*c-xy4Ex;E*^w;EX 9WD77h9DW K{yvcvo’` ,v0$Bh0i _+=+ `~XG.

T-i;s;-o-;fG ,^ G$jjG`|b^ e8F-Q PJszaYP`KYzK f, 4?:c_Xn^_?X $Md)anK al YTY?cT q)49- K LKG?t: e2mA wA^gJFY^TA) 3IQLz[L?s?Lj JL 2B ~9n]y 2(?2 1|_1JEN| f~DcDp J* ZEYY SC 1n !O=VR6FRRO6 88b0 n#|,FA#|HU8* VH bX [_c[ONw_ s=}} E7] X5 ^c!z/&L P%*PUO_6%q-ObUqb*fb6U%T F9H?xU\H ^Pl^2S }JYtH(.

Please login or register for full access

Register

Already registered?  Login